T-APN-Gal-MMAE

T-APN-Gal-MMAE is a **novel antibody-drug conjugate (ADC)** created by conjugating ADPN-modified trastuzumab (a monoclonal antibody targeting ERBB2/HER2) with a cytotoxic payload, *monomethyl auristatin E (MMAE)*, via a β-galactosidase-cleavable linker[1]. The ADPN functional group enables stable rebridging to reduced trastuzumab, while the β-galactosidase-cleavable linker allows for selective drug release within cancer cells. Upon binding and internalization into HER2-positive cancer cells, the linker is cleaved by intracellular β-galactosidase, releasing MMAE, which inhibits tubulin polymerization leading to cell cycle arrest and apoptosis[1][13]. This design provides enhanced specificity and potent cytotoxicity for HER2-positive cancers, showing efficacy comparable to trastuzumab emtansine (T-DM1) and strong selectivity versus HER2-negative cells in preclinical models[1]. The molecule is an experimental candidate developed for targeted therapy in HER2-positive cancers.

Brand names

T-APN-Gal-MMAE

Other names

T-ADPN-Gal-MMAE